文献速递甲状腺疾病

阿司匹林使用与甲状腺癌风险降低无关:一项全国性巢式病例对照研究

Aspirin Use Is Not Associated with Lower Thyroid Cancer Risk: A Nationwide Nested Case-Control Study.
PubMed 文献 · Thyroid · 2020-02-14

该研究基于韩国国民健康保险服务-全国样本队列(2002-2015年)的巢式病例对照设计,纳入4547例新发甲状腺癌患者并按年龄、性别和随访期匹配13641例对照。调整体重指数、吸烟状态、高血压、Charlson合并症指数和每年门诊次数后,阿司匹林使用时长与甲状腺癌风险无显著关联;按年龄、性别和随访时长分层的亚组分析亦未发现显著关联。结论提示即使延长阿司匹林使用也可能不影响甲状腺癌的预防或发生。

要点

  • 阿司匹林使用时长与甲状腺癌风险无显著关联,调整后OR均未达统计学显著。
  • 按年龄、性别和随访时长分层的亚组分析未发现阿司匹林与甲状腺癌的显著关联。
  • 作者认为即使延长阿司匹林使用也可能不影响甲状腺癌的预防或发生。

核心结论

  • 研究结论提示,即使延长阿司匹林使用也可能不影响甲状腺癌的预防或发生。

研究设计与样本

  • 巢式病例对照研究,使用韩国国民健康保险服务-全国样本队列2002-2015年全国性数据。
  • 共纳入4547例新发甲状腺癌患者,按年龄、性别和随访期匹配13641例对照。
  • 采用多变量条件logistic回归模型分析阿司匹林使用与甲状腺癌发生的比值比(OR)和95%置信区间(CI)。

主要发现

  • 甲状腺癌患者与对照的阿司匹林使用天数具有可比性(不使用、每年<30天、每年30-90天、每年≥90天的比例分别为93.03%、6.51%、0.31%、0.15%,卡方检验p=0.371)。
  • 调整体重指数、吸烟状态、高血压、Charlson合并症指数和每年门诊次数后,与不使用相比,每年<30天、每年30-90天、每年≥90天的OR分别为1.11(95%CI 0.96-1.28)、1.01(95%CI 0.54-1.88)、1.23(95%CI 0.50-3.06)。
  • 按年龄、性别和随访时长分层的亚组分析未显示阿司匹林使用与甲状腺癌之间的任何显著关联。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background: While aspirin use is known to be associated with reduced incidence of various cancer types, it is unclear whether this benefit extends to thyroid cancer. We aimed to evaluate the association between aspirin use and thyroid cancer development. Methods: This nested case-control study used nationwide data from the Korean National Health Insurance Service-National Sample Cohort 2002-2015. In total, 4547 individuals with newly developed thyroid cancer were matched with 13,641 controls based on age, sex, and follow-up period. Odds ratios (ORs) and 95% confidence intervals (CIs) for thyroid cancer development according to aspirin use were analyzed using a multivariable conditional logistic regression model. Results: The number of days for which patients with thyroid cancer used aspirin (the proportions of no use, <30 days/year, 30-90 days/year, and ≥90 days/year were 93.03%, 6.51%, 0.31%, and 0.15%, respectively) was comparable with that of the controls (p = 0.371, chi-squared test). The risk of thyroid cancer development was not associated with the duration of aspirin use (ORs [CI] for aspirin use <30 days/year, 30-90 days/year, and ≥90 days/year were 1.11 [0.96-1.28], 1.01 [0.54-1.88], and 1.23 [0.50-3.06], respectively, compared with no use) after adjusting for body mass index, smoking status, hypertension, Charlson comorbidity index, and number of outpatient visits per year. In addition, subgroup analyses stratified by age, sex, and follow-up duration did not reveal any significant association between aspirin use and thyroid cancer. Conclusions: Our findings suggest that even extended aspirin use may not impact the prevention or onset of thyroid cancer.

来源:Thyroid,查看原文。版权归原作者所有。

引用

  1. Lee YK, Hwangbo Y, Lee S, et al. Aspirin Use Is Not Associated with Lower Thyroid Cancer Risk: A Nationwide Nested Case-Control Study. Thyroid. 2020. PMID: 31950888. doi:10.1089/thy.2019.0641

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。